Gene Information
Gene symbol: BARD1
Gene name: BRCA1 associated RING domain 1
HGNC ID: 952
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | AKT1 | 1 hits |
| 2 | ALK | 1 hits |
| 3 | BRAF | 1 hits |
| 4 | BRCA1 | 1 hits |
| 5 | BRCA2 | 1 hits |
| 6 | CD274 | 1 hits |
| 7 | ERBB2 | 1 hits |
| 8 | FGFR1 | 1 hits |
| 9 | IDH2 | 1 hits |
| 10 | KIT | 1 hits |
| 11 | MET | 1 hits |
| 12 | NOTCH1 | 1 hits |
| 13 | PIK3CA | 1 hits |
| 14 | PTEN | 1 hits |
| 15 | RET | 1 hits |
| 16 | RNF19A | 1 hits |
| 17 | STK11 | 1 hits |
| 18 | TP53 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 34789768 | RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination. |
| 2 | 34789768 | RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination. |
| 3 | 34789768 | Dysfunction of the BRCA1 pathway enhances the therapeutic efficiency of poly-(ADP-ribose) polymerase inhibitors (PARPi) in cancers, but the molecular mechanisms underlying this sensitization to PARPi are not fully understood. |
| 4 | 34789768 | Dysfunction of the BRCA1 pathway enhances the therapeutic efficiency of poly-(ADP-ribose) polymerase inhibitors (PARPi) in cancers, but the molecular mechanisms underlying this sensitization to PARPi are not fully understood. |
| 5 | 34789768 | We demonstrate that RNF19A suppresses HR by ubiquitinating BARD1, which leads to dissociation of BRCA1-BARD1 complex and exposure of a nuclear export sequence in BARD1 that is otherwise masked by BRCA1, resulting in the export of BARD1 to the cytoplasm. |
| 6 | 34789768 | We demonstrate that RNF19A suppresses HR by ubiquitinating BARD1, which leads to dissociation of BRCA1-BARD1 complex and exposure of a nuclear export sequence in BARD1 that is otherwise masked by BRCA1, resulting in the export of BARD1 to the cytoplasm. |
| 7 | 35180531 | Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers. |
| 8 | 35180531 | Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel. |
| 9 | 35180531 | Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence). |
| 10 | 35180531 | TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003). |
| 11 | 35180531 | The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P < 0.0001), and a higher Ki-67 index (P = 0.004). |
| 12 | 35180531 | PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%). |
| 13 | 35180531 | The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer. |